Interleukin-6 and interleukin-8 blood levels' poor association with the severity and clinical profile of ex-smokers with COPD

International Journal of COPD

Volumn 9, Issue , 2014, Pages 735-743

  de Moraes, Maria Rosedália ^a   da Costa, Adeliane Castro ^a   Corrêa, Krislainy de Sousa ^a   Junqueira Kipnis, Ana Paula ^a   Rabahi, Marcelo Fouad ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

C reactive protein; COPD; Interleukin 6; Interleukin 8

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; AUTACOID; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BLOOD ANALYSIS; BODY MASS; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EXERCISE TOLERANCE; FEMALE; HUMAN; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; SMOKING HABIT; UPREGULATION; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; EXERCISE TEST; IMMUNOLOGY; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SMOKING; SMOKING CESSATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EXERCISE TEST; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; LUNG; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; SMOKING CESSATION;

EID: 84905244172     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S64135     Document Type: Article

References (39)

1. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002; 121(Suppl5): 121S-126S.
2. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004; 364(9434): 613-620.
3. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009; 360(23): 2445-2454.
4. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003; 167(3): 418-424.
5. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004; 364(9435): 709-721.
6. Saetta M, Di Stefano A, Turato G, et al. CD8+T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157(3 Pt1): 822-826.
7. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33(5): 1165-1185.
8. Aaron SD, Vandemheen KL, Ramsay T, et al. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stableCOPD. Respir Res. 2010; 11: 41.
9. Garcia-Rio F, Miravitlles M, Soriano JB, et al; EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010; 11: 63.
10. Piehl-Aulin K, Jones I, Lindvall B, Magnuson A, Abdel-Halim SM. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration. 2009; 78(2): 191-196.
11. He Z, Chen Y, Chen P, Wu G, Cai S. Local inflammation occurs before systemic inflammation in patients with COPD. Respirology. 2010; 15(3): 478-484.
12. Ferrari R, Tanni SE, Caram LM, Corrêa C, Corrêa CR, Godoy I. Three-year follow-up of Interleukin6and C-reactive protein in chronic obstructive pulmonary disease. Respir Res. 2013; 14: 24.
13. Garcia-Aymerich J, Gómez FP, Benet M, et al; PAC-COPD Study Group. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011; 66(5): 430-437.
14. Agustí A, Edwards LD, Rennard SI, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012; 7(5): e37483.
15. Yao H, Rahman I. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol. 2011; 254(2): 72-85.
16. Liu J, Liang Q, Frost-Pineda K, et al. Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2011; 20(8): 1760-1769.
17. Willemse BW, ten Hacken NH, Rutgers B, Postma DS, Timens W. Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers. Respir Res. 2005; 6: 38.
18. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD: GOLD Revised2011. Available from: http://www. goldcopd. org/uploads/users/files/GOLD_Report_2011_Jan21. pdf. Accessed May20, 2011.
19. Ciba Foundation Guest Symposium. Terminology, definition and classification of chronic pulmonary emphysema and related conditions. Thorax. 1959; 14(4): 286-299.
20. Menezes AM. Epidemiologia da bronquite crônica e do enfisema (DPOC): até onde sabemos? [Bronchitis and emphysema epidemiology: what do we know?] J Pneumol. 1997; 23(3): 153-157. Portugese.
21. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005; 26(2): 319-338.
22. Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007; 33(4): 397-406.
23. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1): 111-117.
24. Donaldson GC, Seemungal TAR, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128(4): 1995-2004.
25. Celli BR, Locantore N, Yates J, et al; ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 185(10): 1065-1072.
26. Pinto-Plata V, Casanova C, Mullerova H, et al. Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respir Res. 2012; 13: 71.
27. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stablechronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 178(12): 1211-1218.
28. Breyer MK, Rutten EP, Vernooy JH, et al. Gender differences in the adipose secretome system in chronic obstructive pulmonary disease (COPD): a pivotal role of leptin. Respir Med. 2011; 105(7): 1046-1053.
29. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(10): 1005-1012.
30. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008; 31(3): 492-501.
31. Morales SA, Dreyse DJ, Díaz PO, Saldías PF, Carrasco M, Lisboa BC. [Systemic inflammation among stable ex smokers with chronic obstructive pulmonary disease]. Rev Med Chil. 2010; 138(8): 957-964. Spanish.
32. de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest. 2008; 133(6): 1336-1343.
33. Izquierdo JL, Almonacid C, Parra T, Pérez J. [Systemic and lung inflammation in2 phenotypes of chronic obstructive pulmonary disease]. Arch Bronconeumol. 2006; 42(7): 332-337. Spanish.
34. Van der Vaart H, Postma DS, Timens W, et al. Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res. 2005; 6: 22.
35. Willemse BW, ten Hacken NH, Rutgers B, Postma DS, Timens W. Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers. Respir Res. 2005; 6: 38.
36. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009; 136(4): 1039-1046.
37. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186(10): 982-988.
38. Divo M, Cote C, de Torres JP, et al; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186(2): 155-161.
39. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003; 107(11): 1514-1519.